BioCryst Pharmaceuticals has unveiled groundbreaking clinical data for ORLADEYO at the 2025 Meeting of the European Academy of Allergy and Clinical Immunology. The new findings demonstrate significant advancements in the HAE (Hereditary Angioedema) treatment landscape, particularly concerning pediatric patients. The data reveal ORLADEYO’s efficacy in reducing attack frequency and improving the quality of life for young patients living with HAE. This breakthrough positions ORLADEYO as a potentially game-changing oral therapy, offering new hope for children previously reliant on less convenient treatment methods. The results not only highlight the drug’s beneficial impact on managing HAE but also reinforce BioCryst’s commitment to innovation in rare disease therapeutics. By offering a more manageable treatment option, ORLADEYO could transform how pediatric patients and their families approach living with HAE, making day-to-day life significantly easier and more predictable.
Stock TitanNew data shows 90% of buyers unable to afford new Brisbane apartments
April 29, 2026
In Brisbane, a startling new statistic reveals that nine out of ten potential buyers are priced out of the city’s new apartment market. With soaring